Imlunestrant shows efficacy both with and without abemaciclib


Play all audios:

Access through your institution Buy or subscribe Various endocrine therapies and CDK4/6 inhibitors have improved the treatment of ER+HER2−breast cancer, although resistance remains common


and often involves _ESR1_ (encoding ERα) mutations. Now, data from the phase III EMBER-3 trial demonstrate that the next-generation, brain-penetrant, oral selective ER degrader imlunestrant


delays disease progression in previously treated patients with _ESR1_ mutations, and regardless of _ESR1_ status when combined with abemaciclib. In EMBER-3, patients with progression of ER+


HER2− breast cancer during or ≤1 year after completing (neo)adjuvant therapy with an aromatase inhibitor, or during first-line treatment for advanced-stage disease, were randomly assigned to


receive imlunestrant (_n_ = 331), standard endocrine therapy (exemestane or fulvestrant; _n_ = 330), or imlunestrant–abemaciclib (_n_ = 213). The majority of patients (59.8%) had also


received a prior CDK4/6 inhibitor, most for advanced-stage disease. The primary end points were progression-free survival (PFS) with imlunestrant versus standard therapy among patients with


_ESR1_ mutations and among all patients, and with imlunestrant–abemaciclib versus imlunestrant among all patients. This is a preview of subscription content, access via your institution


ACCESS OPTIONS Access through your institution Access Nature and 54 other Nature Portfolio journals Get Nature+, our best-value online-access subscription $32.99 / 30 days cancel any time


Learn more Subscribe to this journal Receive 12 print issues and online access $209.00 per year only $17.42 per issue Learn more Buy this article * Purchase on SpringerLink * Instant access


to full article PDF Buy now Prices may be subject to local taxes which are calculated during checkout ADDITIONAL ACCESS OPTIONS: * Log in * Learn about institutional subscriptions * Read our


FAQs * Contact customer support REFERENCES ORIGINAL ARTICLE * Jhaveri, K. L. et al. Imlunestrant with or without abemaciclib in advanced breast cancer. _N. Engl. J. Med._


https://doi.org/10.1056/NEJMoa2410858 (2024) Article  PubMed  Google Scholar  Download references AUTHOR INFORMATION AUTHORS AND AFFILIATIONS * Nature Reviews Clinical Oncology


http://www.nature.com/nrclinonc David Killock Authors * David Killock View author publications You can also search for this author inPubMed Google Scholar CORRESPONDING AUTHOR Correspondence


to David Killock. RIGHTS AND PERMISSIONS Reprints and permissions ABOUT THIS ARTICLE CITE THIS ARTICLE Killock, D. Imlunestrant shows efficacy both with and without abemaciclib. _Nat Rev


Clin Oncol_ 22, 157 (2025). https://doi.org/10.1038/s41571-024-00983-y Download citation * Published: 02 January 2025 * Issue Date: March 2025 * DOI:


https://doi.org/10.1038/s41571-024-00983-y SHARE THIS ARTICLE Anyone you share the following link with will be able to read this content: Get shareable link Sorry, a shareable link is not


currently available for this article. Copy to clipboard Provided by the Springer Nature SharedIt content-sharing initiative